NASDAQ:VERA Vera Therapeutics (VERA) Stock Price, News & Analysis $28.89 -1.10 (-3.67%) Closing price 08/13/2026 04:00 PM EasternExtended Trading$30.63 +1.74 (+6.02%) As of 04:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vera Therapeutics Stock (NASDAQ:VERA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vera Therapeutics alerts:Sign Up Key Stats Today's Range$28.86▼$30.1150-Day Range$28.89▼$43.1552-Week Range$21.04▼$56.05Volume1.13 million shsAverage Volume1.89 million shsMarket Capitalization$2.07 billionP/E RatioN/ADividend YieldN/APrice Target$81.15Consensus RatingModerate Buy Company Overview Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity. Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs. The company concentrates on high-unmet-need autoimmune disorders, pursuing therapies that can broadly benefit patient populations worldwide. Through strategic partnerships and disciplined clinical execution, Vera Therapeutics seeks to accelerate the translation of its immunomodulatory candidates. The leadership team at Vera Therapeutics brings extensive experience in biologics development, translational research and regulatory affairs, supported by an accomplished scientific advisory board. As a NASDAQ‐listed company trading under the ticker VERA, it is well positioned to drive its innovative platform toward key clinical milestones and deliver new treatment options for immune-mediated diseases.AI Generated. May Contain Errors. Read More Vera Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreVERA MarketRank™: Vera Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 260th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingVera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVera Therapeutics has a consensus price target of $81.15, representing about 180.9% upside from its current price of $28.89.Amount of Analyst CoverageVera Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vera Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vera Therapeutics are expected to grow in the coming year, from ($6.45) to ($4.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vera Therapeutics is -4.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vera Therapeutics is -4.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVera Therapeutics has a P/B Ratio of 3.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.31% of the float of Vera Therapeutics has been sold short.Short Interest Ratio / Days to CoverVera Therapeutics has a short interest ratio ("days to cover") of 9.42.Change versus previous monthShort interest in Vera Therapeutics has recently increased by 1.33%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVera Therapeutics does not currently pay a dividend.Dividend GrowthVera Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.60 News SentimentVera Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Vera Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 45 people have searched for VERA on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,658,080.00 in company stock.Percentage Held by Insiders15.90% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vera Therapeutics' insider trading history. Receive VERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VERA Stock News HeadlinesHC Wainwright Lowers Vera Therapeutics (NASDAQ:VERA) Price Target to $90.002 hours ago | americanbankingnews.comWedbush Issues Pessimistic Forecast for Vera Therapeutics (NASDAQ:VERA) Stock PriceAugust 13 at 2:01 AM | americanbankingnews.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | Profits Run (Ad)Analysts Offer Insights on Healthcare Companies: Clinigence Holdings (NUTX), Vera Therapeutics (VERA) and Solid Biosciences (SLDB)August 12 at 10:50 PM | theglobeandmail.comVera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial ResultsAugust 10, 2026 | markets.businessinsider.comSilence Therapeutics shares surge ahead of divesiran Phase 2 results callAugust 10, 2026 | finance.yahoo.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 7, 2026 | globenewswire.comVera Therapeutics Inc - Ordinary Shares - Class AJuly 13, 2026 | money.usnews.comSee More Headlines VERA Stock Analysis - Frequently Asked Questions How have VERA shares performed this year? Vera Therapeutics' stock was trading at $50.64 at the beginning of the year. Since then, VERA shares have decreased by 43.0% and is now trading at $28.89. How were Vera Therapeutics' earnings last quarter? Vera Therapeutics, Inc. (NASDAQ:VERA) released its quarterly earnings results on Monday, August, 10th. The company reported ($1.52) EPS for the quarter, topping analysts' consensus estimates of ($1.58) by $0.06. When did Vera Therapeutics IPO? Vera Therapeutics (VERA) raised $65 million in an initial public offering on Thursday, May 13th 2021. The company issued 4,350,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI acted as the underwriters for the IPO. Who are Vera Therapeutics' major shareholders? Vera Therapeutics' top institutional shareholders include E. Ohman J or Asset Management AB (0.12%), Hennion & Walsh Asset Management Inc. (0.06%) and Handelsbanken Fonder AB (0.03%). Insiders that own company stock include Commodore Capital Lp, Maha Katabi, Marshall Fordyce, Beth C Seidenberg, Sean Grant, Joseph R Young, Laurence Matthew Skelton, Robert Brenner, David Lee Johnson, William D Turner, Celia Lin and Patrick G Enright. View institutional ownership trends. How do I buy shares of Vera Therapeutics? Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vera Therapeutics investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings8/10/2026Today8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 4 weeks, VERA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VERA CIK1831828 Webveratx.com Phone650-770-0077FaxN/AEmployees40Year Founded2016Price Target and Rating Average Price Target for Vera Therapeutics$81.15 High Price Target$125.00 Low Price Target$34.00 Potential Upside/Downside+180.9%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($5.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$299.61 million Net MarginsN/A Pretax MarginN/A Return on Equity-80.21% Return on Assets-64.34% Debt Debt-to-Equity Ratio0.15 Current Ratio13.64 Quick Ratio13.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.48 per share Price / Book3.41Miscellaneous Outstanding Shares71,780,000Free Float60,370,000Market Cap$2.07 billion OptionableOptionable Beta0.92 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:VERA) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersIran War: What Happened at 1:11 P.M. Outside D.C.?A source with ties to Saudi Arabia, the UAE, and the U.S. State Department revealed details of a potential 7 t...Banyan Hill Publishing | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredElon’s S-1 Master Plan Could Rewrite the Rules of AIA researcher who has advised Goldman Sachs, JPMorgan Chase, BlackRock, and Fidelity flew to Starbase after spo...Altimetry | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
